GCIA
CERE

Gabelli & Co Investment Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-164,345
Closed -$6.72M – 288
2024
Q2 		$6.72M Sell
164,345
-283,350
-63% -$11.8M 1.12% 26
2024
Q1 		$18.9M Buy
447,695
+172,195
+63% +$7.23M 3.29% 4
2023
Q4 		$11.7M Buy
+275,500
New +$7.92M 2.19% 13

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Gabelli & Co Investment Advisers's CERE Position: Q3 2024 in Review

Gabelli & Co Investment Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 164,345 shares — an estimated $6.72M sold.

Gabelli & Co Investment Advisers first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $18.9M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Gabelli & Co Investment Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 164,345 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $6.72M.
  • Gabelli & Co Investment Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Gabelli & Co Investment Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $18.9M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.